Evidence supporting a correlation between arachidonic acid release and prolactin secretion from GH3 cells.

In this study, pharmacological agents that alter phospholipase A2 activity were examined for their effects on PRL release and arachidonic acid mobilization in GH3 cells, a pituitary tumor cell line. Stimulators of phospholipase A2 activity, melittin and mastoparan, increased PRL release during short term incubation. This stimulation was reduced by carbachol, a cholinergic receptor ligand that inhibits PRL release from GH3 cells. Melittin also caused release of [3H]arachidonic acid that had previously been incorporated into phospholipids. Increased levels of free [3H]arachidonic acid in the medium were associated with a loss of radiolabel from the phospholipid fraction of the cells. The [3H]arachidonic acid in phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol was reduced during melittin exposure. In contrast, two inhibitors of phospholipase A2, dibromoacetophenone (BAP) and U10029A, inhibited spontaneous PRL release. BAP also decreased basal release of [3H]arachidonic acid, blocked melitin-induced PRL secretion, and inhibited melittin-induced [3H] arachidonic acid release. Exogenous arachidonic acid at doses from 10 nM to 1 microM stimulated PRL secretion. The phospholipase A2 inhibitor BAP blocked TRH- and vasoactive intestinal peptide-induced PRL release, whereas U10029A blocked cAMP-induced and blunted TRH- and vasoactive intestinal peptide-induced PRL release. The hydrolysis of membrane phospholipids generating free arachidonic acid and lysophospholipid under our experimental conditions correlated with PRL secretion in GH3 cells. Addition of arachidonic acid to the culture medium stimulated PRL secretion. These data suggest that release of arachidonic acid and its subsequent actions may participate in the intracellular regulation of PRL secretion.